✦ LIBER ✦

Translating cell biology into therapeutic advances in Alzheimer's disease

✍ Scribed by Selkoe, Dennis J.

Book ID: 109800172
Publisher: Nature Publishing Group
Year: 1999
Tongue: English
Weight: 316 KB
Volume: 399
Category: Article
ISSN: 0028-0836
DOI: 10.1038/399a023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Advances in the development of kinase in

Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease

✍ Mary J. Savage; Diane E. Gingrich 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 576 KB

## Abstract Pharmaceutical approaches to slow the progression of Alzheimer's disease (AD) have focused primarily on reducing production or increasing clearance of amyloid β peptide (Aβ). Recent clinical trial results question the efficacy of targeting Aβ for treatment of mild to moderate AD, highli

Huntington disease: Advances in molecula

Huntington disease: Advances in molecular and cell biology

✍ A. L. Jones; J. D. Wood; P. S. Harper 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 167 KB

The role and therapeutic potential of mo

The role and therapeutic potential of monocytic cells in Alzheimer's disease

✍ Tarja Malm; Milla Koistinaho; Anu Muona; Johanna Magga; Jari Koistinaho 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB 👁 1 views

## Abstract Alzheimer's disease (AD) is a dementing neurodegenerative disorder without a cure. The abnormal parenchymal accumulation of β‐amyloid (Aβ) is associated with inflammatory reactions involving microglia and astrocytes. Increased levels of Aβ and Aβ deposition in the brain are thought to c

Mechanisms of cell death and disease: Ad

Mechanisms of cell death and disease: Advances in therapeutic intervention

✍ Graham Packham 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 50 KB

Advanced glycation end products co-local

Advanced glycation end products co-localized with astrocytes and microglial cells in Alzheimer’s disease brain

✍ Akinori Takeda; Takeshi Yasuda; Toshio Miyata; Yoji Goto; Masakazu Wakai; Masaki 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 381 KB

Development of M1 subtype selective musc

Development of M1 subtype selective muscarinic agonists for Alzheimer's disease: Translation of in vitro selectivity into in vivo efficacy

✍ R.D. Schwarz; M.J. Callahan; R.E. Davis; J.C. Jaen; H. Tecle 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

Clinical trials in Alzheimer's disease (AD) with first generation muscarinic agonists (e.g., arecoline, oxotremorine, pilocarpine) produced inconsistent results due to poor pharmacokinetic properties and a lack of separation between central and peripheral activities observed with these compounds. Se